Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Therapeutic antibodies targeting programmed cell death 1 (PD-1) are effective against melanoma by activating anti-tumor immunity.
• The role of the PD-1 pathway within cancer cells themselves, particularly in melanoma, remains largely unexplored.

Purpose of the Study:

• To investigate the cell-intrinsic functions of the PD-1 pathway in melanoma development and progression.
• To determine if inhibiting melanoma cell-intrinsic PD-1 can suppress tumor growth.

Main Methods:

• Analysis of PD-1 expression in murine and human melanoma cell subpopulations.
• Inhibition of melanoma cell-intrinsic PD-1 using RNA interference (RNAi), blocking antibodies, and mutagenesis.
• Assessment of tumor growth in various mouse models, including immunocompetent, immunocompromised, and PD-1-deficient recipients.
• Overexpression and ligand (PD-L1) engagement studies of melanoma-PD-1.
• Investigation of downstream signaling pathways, including mTOR.

Main Results:

• PD-1-expressing cancer subpopulations were identified in both murine and human melanomas.
• Melanoma cell-intrinsic PD-1 was found to promote tumorigenesis, independent of adaptive immunity.
• Inhibition of melanoma-PD-1 significantly suppressed tumor growth across different immunocompetent and immunocompromised models.
• Overexpression of melanoma-PD-1 or engagement by PD-L1 enhanced tumorigenicity.
• Melanoma-PD-1 signaling was mechanistically linked to the modulation of mTOR signaling.

Conclusions:

• The PD-1:PD-L1 axis exerts cell-intrinsic functions in melanoma growth.
• Targeting melanoma cell-intrinsic PD-1 represents a potential therapeutic strategy to enhance the efficacy of anti-PD-1 therapies.
• Blocking melanoma-PD-1 may offer a novel approach to combatting melanoma, complementing current immunotherapies.